Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX
Cumberland Pharmaceuticals — Q4 2025 Earnings Presentation
31 slides from Cumberland Pharmaceuticals's earnings presentation, Mar 3, 2026
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq CPIX
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements Important factors that could cause actual results to differ concerning our approved products and product materially from those indicated by such forward-looking development, our technology, our competitors, our statements in
Slide 3: Nation's Health Care Capital
Nation’s Health Care Capital 3
Slide 4: Company Overview
Company Overview Specialty pharmaceutical company Portfolio of FDA approved branded products Promoted by three national sales divisions Several catalysts for new growth opportunities Sancuso® post-acquisition integration and market expansion Next Generation Caldolor ® product with expanded labeling
Slide 5: Mission & Strategy
Mission & Strategy Mission: Working together to provide unique products that improve the quality of patient care Strategy: We are building a portfolio of specialized biopharmaceutical brands 5
Slide 6: Product Portfolio
Product Portfolio Product Development: Product Acquisition: 6
Slide 7: Acetadote: IV treatment for acetaminophen overdose
• IV treatment for America’s leading cause of poisoning • Treats liver toxicity associated with acetaminophen overdose • Acetadote (IV N-Acetylcysteine) developed and registered by Cumberland • IV N-Acetycysteine now standard of care • Cumberland developed unique EDTA free formulation • New dosing r
Slide 8: Caldolor (ibuprofen) Injection
(“ALDOLOR’ CALDOLOR’ | 4 (ibuprofen) Injection | (ibuprofen) Injection a 5
Slide 9: Caldolor: injectable ibuprofen
• Injectable delivery of ibuprofen • Developed and registered by Cumberland • Antipyretic, analgesic & anti-inflammatory properties • Evaluated in published studies with ~ 2,000 patients • Approved for use in adults, children and newborns • Prior to surgery administration approved by FDA • New data
Slide 10: Kristalose
freedom TO go &... -KRISTALOSE’ = BE ulose) For Oral Solu
Slide 11: Kristalose: crystalline lactulose
• Unique crystalline formulation of lactulose • Prescription strength laxative • Clinically proven increase in patient satisfaction • Featured in award winning marketing campaign • Supported by key co-promotion partners • New initiatives underway to protect and grow business 11
Slide 12: Vibativ (telavancin) for injection
WY visp«~ ~*_{telavancin) for S WY VIBATIV’ (telavancin) for injection C= CUMBERLAND" > wf
Slide 13: Vibativ: IV antibiotic
• IV antibiotic that treats life-threatening infections • Potent treatment for pneumonia and serious skin infections resulting from gram positive bacteria • Used in hospital acute care and out-patient center settings • Unique ability to penetrate tissues • Product features favorable resistance profi
Slide 14: Sancuso (Granisetron Transdermal System)
Sancuso’ (Granisetron Transdermal System) ONLY. ~~ Sancuso > (Graniselron Transdermal System} 14. years experience Preve ntion of CINV' Keeps [aaa ji covered isetton transdermal system! is indicated for the prevention of nausea and vomiting n adults receiving moderately and/or highly emetogenic chem
Slide 15: Sancuso: transdermal system for CINV
• FDA-approved transdermal system for chemotherapy- induced nausea and vomiting • Patch that slowly releases medicine into bloodstream • Designed to prevent nausea and vomiting in adults to help tolerate certain chemotherapy treatments • Medicine delivered over five consecutive days compared with mu
Slide 16: Talicia
=Talicia. (omeprazole magnesium, amoxicillin, and rifabutin) Convenience of UNIQUE ALL-IN-ONE-FORMULATION Talicia® is indicated for the treatment of Helicobacter pylori stomach infections in adults The leading risk factor for gastric cancer + High H. pylori eradication rates regardless of resistance
Slide 17: Talicia: all-in-one capsule for H. pylori
• FDA-approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer • A fixed-dose, all-in-one capsule combination of two antibiotics, amoxicillin and rifabutin, and a proton pump inhibi
Slide 18: Ifetroban Overview
Ifetroban Overview • Cumberland’s first new chemical entity • A potent, selective antagonist of thromboxane receptor • Discovered and initially developed by Bristol-Myers Squibb • Safety well-established in 30 clinical studies with over 1,400 subjects • Collaborating with Vanderbilt, Harvard, Scripp
Slide 19: Ifetroban Development Pipeline
Ifetroban Development Pipeline Preclinical IND Phase I Phase II Phase III NDA Dyscorban ® (Duchenne muscular dystrophy) Vasculan ® (Systemic sclerosis) Fibroban ® (Idiopathic Pulmonary Fibrosis) 19
Slide 20: Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) • A rare, fatal, neuromuscular disease with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs • Cumberland is investigating ifetroban for the treatment of cardiomyopathy that is associated with DMD • Preclinical data demonstr
Slide 21: Systemic Sclerosis (SSc)
Systemic Sclerosis (SSc) • Debilitating, chronic autoimmune disease causing thickening of the skin and fibrosis of internal organs • Highest death rate of any rheumatic condition • Average survival is approximately 11 years from diagnosis • Women more commonly affected; also occurs in children • No
Slide 22: Fibroban in IPF
Fibroban® in IPF • Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) are a group of disorders that causes irreversible scarring (fibrosis) of lung tissue that leads to lung function decline and early mortality • Idiopathic Pulmonary Fibrosis (IPF) is the most common form of PF-ILDs • Orphan
Slide 23: Slide 23
Slide 24: Academic research partnerships and Nashville Life Science Center
• Joint initiative to build long term pipeline • Collaborating with Academic Research Partners • Building portfolio of innovative biopharmaceutical candidates • Supporting product development through grant initiatives • Managing Nashville’s Life Science Center • Houses Cumberland’s formulation and t
Slide 25: Building a Diversified Product Portfolio
Building a Diversified Product Portfolio Ifetroban Next Gen In-Line Brands Deploying a Multifaceted Strategy to Create Value 25
Slide 26: Commercial Portfolio Expansion Strategy
Commercial Portfolio Expansion Strategy EXPAND DEVELOP Existing Products Early-Stage Candidates PRODUCT PORTFOLIO IDENTIFY ACQUIRE Late Stage Candidates Under-Promoted, Approved Brands 26
Slide 27: Acquisition Initiative
Acquisition Initiative Active, ongoing initiative to identify, evaluate and acquire/license new products into the portfolio Source opportunities through direct efforts and intermediaries GOAL TO ADD ONE NEW Seek commercial and late stage development PRODUCT PER YEAR assets that fit our strategy and f
Slide 28: Income Statement
Income Statement ($ IN MILLIONS) FY 2025 Net Revenues $ 44.5 Cost of Products Sold 6.7 Gross Profit 37.8 Selling & Marketing 19.1 Research & Development 5.6 General Administrative 11.6 Amortization 4.0 Adjusted Earnings 2.1 Cash flow from operations 4.9 28 28
Slide 29: Summary Balance Sheet
Summary Balance Sheet ($ in millions) Dec 31, 2025 Cash and Securities $11 Total Assets 77 Total Liabilities 52 Total Equity 25 Total Liabilities and Equity $77 *tax carryforward credits of $54 million available 29 29
Slide 30: Cumberland Moving Forward
Cumberland Moving Forward Diverse product portfolio of FDA approved brands Proven development and commercialization capabilities Various initiatives in place to support near-term growth Phase II products in development with study results milestones Valuation gap given level of sales, assets, infrast
Slide 31: NASDAQ: CPIX
NASDAQ: CPIX
Cumberland Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix